Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease

Hum Gene Ther. 1998 May 20;9(8):1237-50. doi: 10.1089/hum.1998.9.8-1237.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Cell Line
  • Drug Resistance, Microbial / genetics
  • Feasibility Studies
  • Genes, Viral
  • Genetic Markers*
  • Genetic Vectors
  • Herpesvirus 4, Human / genetics*
  • Hodgkin Disease / virology*
  • Humans
  • Injections, Intravenous
  • Neomycin / pharmacology*
  • Neoplasm Recurrence, Local
  • Retroviridae / genetics
  • T-Lymphocytes, Cytotoxic*

Substances

  • Anti-Bacterial Agents
  • Genetic Markers
  • Neomycin